| Rheumatoid Arthritis
Cimzia vs Kineret
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Cimzia vs Kineret with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKineret has a higher rate of injection site reactions vs Cimzia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kineret but not Cimzia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cimzia
Kineret
At A Glance
SC injection
Every 2-4 weeks
TNF-alpha inhibitor
SC injection
Daily
IL-1 receptor antagonist
Indications
- Crohn Disease
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Psoriasis vulgaris
- Rheumatoid Arthritis
- Chronic Infantile Neurological, Cutaneous, and Articular Syndrome
- INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
Dosing
Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.
Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).
Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.
Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.
Rheumatoid Arthritis 100 mg/day SC; administer every other day in severe renal insufficiency or ESRD (creatinine clearance <30 mL/min).
Chronic Infantile Neurological, Cutaneous, and Articular Syndrome Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; once daily or split into twice daily; administer every other day in severe renal insufficiency or ESRD.
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; administer every other day in severe renal insufficiency or ESRD.
Contraindications
- History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)
- Known hypersensitivity to E. coli-derived proteins, anakinra, or any components of the product
Adverse Reactions
Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)
Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression
Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma
Most common (>=5%) Injection site reaction, worsening of RA, upper respiratory tract infections, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain
Serious Serious infections (cellulitis, pneumonia, bone and joint infections), neutropenia (particularly in combination with TNF blocking agents), lymphoma, other malignancies
Postmarketing Transaminase elevations, non-infectious hepatitis, thrombocytopenia (including severe), DRESS, injection site amyloid deposits
Pharmacology
Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.
IL-1 receptor antagonist; anakinra is a recombinant human IL-1Ra that competitively inhibits IL-1alpha and IL-1beta binding to the interleukin-1 type I receptor (IL-1RI), blocking downstream inflammatory and immunological responses including cartilage degradation and bone resorption.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cimzia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Kineret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Cimzia
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Kineret
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Humana
Cimzia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Kineret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cimzia.
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CimziaView full Cimzia profile
KineretView full Kineret profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.